Table 5.
Polymorphisms of genes in folic pathway and overall survival
| Genotype | Frequency (%) | Median Overall Survival in months (95% CI) | |
|---|---|---|---|
| TS 3′ | +/+ | 14/22 (64%) | 7 (4 – 13) |
| +/− | 6/22 (27%) | 7 (2–7) | |
| −/− | 2/22 (9%) | 9 (2 - n.r.) | |
| TS 5′ | 2R/2R | 6/22 (27%) | 13 (4 – 13) |
| 2R/3R | 14/22 (64%) | 7 (2–9) | |
| 3R/3R | 2/22 (9%) | 15 (2-n.r.) | |
| TS 5′ GC | 2R/2R | 6/22 (27%) | 13 (4–13) |
| 2R/3R(C) | 8/22 (36%) | 9 (2–9) | |
| 3R(C)/3R(C) | 2/22 (9%) | 15 (2-n.r.) | |
| 2R/3R(G) | 6/22 (27%) | 7 (2–7) | |
| 3R(G)/3R(C) | 0/22 (0%) | · | |
| 3R(G)/3R(G) | 0/22 (0%) | · | |
| TS 5′ Functional Significance | LOW | 16/22 (73%) | 9 (4–12) |
| INTERMEDIATE | 6/22 (27%) | 7 (2–7) | |
| HIGH | 0/22 (0%) | · | |
| MTHFR C677T | C/C | 11/22 (50%) | 6 (4–9) |
| C/T | 11/22 (50%) | 7 (2–13) | |
| T/T | 0/22 (0%) | · | |
| MTHFR A1298C | A/A | 11/22 (50%) | 7 (4–12) |
| A/C | 8/22 (36%) | 4 (2–6) | |
| C/C | 3/22 (14%) | 9 (5–9) | |
| RRMI G/A | G/G | 9/22 (41%) | 7 (4–7) |
| G/A | 10/22 (45%) | 9 (2–12) | |
| A/A | 3/22 (14%) | 5 (4–5) | |
| CDA A79C | A/A | 8/21 (38%) | 4 (2–5) |
| A/C | 12/21 (57%) | 7 (5–9) | |
| C/C | 1/21 (5%) | · | |